Compare MIND & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | ATYR |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 73.7M |
| IPO Year | N/A | N/A |
| Metric | MIND | ATYR |
|---|---|---|
| Price | $7.62 | $0.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 155.8K | ★ 998.5K |
| Earning Date | 04-21-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.45 | $0.64 |
| 52 Week High | $14.50 | $7.29 |
| Indicator | MIND | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 36.57 |
| Support Level | $7.61 | $0.67 |
| Resistance Level | $9.26 | $0.85 |
| Average True Range (ATR) | 0.69 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 1.21 | 11.12 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).